Bristol-Myers Squibb Says Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics To Cobenfy
March 28 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL-MYERS SQUIBB: OPEN LABEL OUTPATIENT SWITCH STUDY DEMONSTRATES SYMPTOM STABILITY DURING TRANSITION FROM ORAL ATYPICAL ANTIPSYCHOTICS TO COBENFY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.